Everolimus and Exemestane
About
Membership operator: AND
Therapies: 2
Therapies
Everolimus (tx:ncit:C48387)
Exemestane (tx:ncit:C1097)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | ER positive, HER2-negative | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| EMA (1) FDA (2) | HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| EMA (1) FDA (2) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane |